Endo International PLC (NASDAQ:ENDP) Earns Market Perform Rating from BMO Capital Markets

BMO Capital Markets reiterated their market perform rating on shares of Endo International PLC (NASDAQ:ENDP) in a report released on Friday morning. BMO Capital Markets currently has a $11.00 target price on the stock, down from their previous target price of $15.00.

Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity set a $14.00 price objective on shares of Endo International PLC and gave the stock a hold rating in a research note on Monday, May 1st. Guggenheim initiated coverage on shares of Endo International PLC in a research note on Saturday, June 17th. They issued a hold rating and a $12.00 price objective on the stock. Cowen and Company restated a hold rating and issued a $16.00 price objective on shares of Endo International PLC in a research note on Thursday. Oppenheimer Holdings, Inc. restated a hold rating on shares of Endo International PLC in a research note on Thursday, June 8th. Finally, Deutsche Bank AG lowered their price objective on shares of Endo International PLC from $18.00 to $15.00 and set a buy rating on the stock in a research note on Friday, July 7th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $14.86.

Shares of Endo International PLC (ENDP) traded up 0.79% during mid-day trading on Friday, hitting $7.65. 10,478,200 shares of the company traded hands. The firm’s market cap is $1.71 billion. The firm has a 50-day moving average price of $10.93 and a 200 day moving average price of $11.55. Endo International PLC has a 52-week low of $7.41 and a 52-week high of $24.93.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the consensus estimate of $0.74 by $0.19. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The company had revenue of $875.73 million for the quarter, compared to the consensus estimate of $832.66 million. During the same quarter last year, the company posted $0.86 earnings per share. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. Equities research analysts anticipate that Endo International PLC will post $3.52 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was originally reported by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at [[permalink]].

In other Endo International PLC news, COO Terrance J. Coughlin bought 20,000 shares of the stock in a transaction dated Thursday, August 10th. The stock was bought at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the purchase, the chief operating officer now owns 181,369 shares in the company, valued at approximately $1,396,541.30. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.50% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the stock. James Investment Research Inc. acquired a new stake in shares of Endo International PLC during the second quarter worth $113,000. Macquarie Group Ltd. raised its stake in shares of Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. OppenheimerFunds Inc. raised its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares during the period. Hartford Investment Management Co. acquired a new stake in shares of Endo International PLC during the first quarter worth $1,363,000. Finally, Ameriprise Financial Inc. raised its stake in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after buying an additional 483,545 shares during the period. Institutional investors own 92.27% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.